| アブストラクト | BACKGROUND: Variability in low-density lipoprotein cholesterol (LDL-C) response to statins is underappreciated. We characterised patients by their statin response (SR), baseline risk of cardiovascular disease (CVD) and 10-year CVD outcomes. METHODS AND RESULTS: A multivariable model was developed using 183,213 United Kingdom (UK) patients without CVD to predict probability of sub-optimal SR, defined by guidelines as <40% reduction in LDL-C. We externally validated the model in a Hong Kong (HK) cohort (n = 170,904). Patients were stratified into four groups by predicted SR and 10-year CVD risk score: [SR1] optimal SR & low risk; [SR2] sub-optimal SR & low risk; [SR3] optimal SR & high risk; [SR4] sub-optimal SR & high risk; and 10-year hazard ratios (HR) determined for first major adverse cardiovascular event (MACE). Our SR model included 12 characteristics, with an area under the curve of 0.70 (95% confidence interval [CI] 0.70-0.71; UK) and 0.68 (95% CI 0.67-0.68; HK). HRs for MACE in predicted sub-optimal SR with low CVD risk groups (SR2 to SR1) were 1.39 (95% CI 1.35-1.43, p<0.001; UK) and 1.14 (95% CI 1.11-1.17, p<0.001; HK). In both cohorts, patients with predicted sub-optimal SR with high CVD risk (SR4 to SR3) had elevated risk of MACE (UK HR 1.36, 95% CI 1.32-1.40, p<0.001: HK HR 1.25, 95% CI 1.21-1.28, p<0.001). CONCLUSIONS: Patients with sub-optimal response to statins experienced significantly more MACE, regardless of baseline CVD risk. To enhance cholesterol management for primary prevention, statin response should be considered alongside risk assessment. |
|---|
| ジャーナル名 | PloS one |
|---|
| 投稿日 | 2021/12/3 |
|---|
| 投稿者 | Weng, Stephen Franklin; Akyea, Ralph Kwame; Man, Kenneth Kc; Lau, Wallis C Y; Iyen, Barbara; Blais, Joseph Edgar; Chan, Esther W; Siu, Chung Wah; Qureshi, Nadeem; Wong, Ian C K; Kai, Joe |
|---|
| 組織名 | Primary Care Stratified Medicine (PRISM), Division of Primary Care, University of;Nottingham, Nottingham, United Kingdom.;Centre for Medicine Optimisation Research and Education (CMORE), Research;Department of Practice and Policy, UCL School of Pharmacy, London, United;Kingdom.;Centre for Safe Medication Practice and Research, Department of Pharmacology and;Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong,;China.;Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine,;University of Hong Kong, Hong Kong, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34855879/ |
|---|
